Does Aetna (CVS Health) Cover Finasteride?
A detailed breakdown of Aetna's finasteride coverage policies, formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial, with real dose and cost figures.
71 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 60 of 71 clinical reviews.
A detailed breakdown of Aetna's finasteride coverage policies, formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial, with real dose and cost figures.
A clinical and insurance guide to Anthem (Elevance Health) finasteride coverage, prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial.
A detailed guide to Cigna's finasteride coverage for hair loss and BPH: formulary tier, prior authorization requirements, step therapy, appeal strategies, and cost-saving options.
A clinical guide to Kaiser Permanente's formulary status, prior authorization criteria, step therapy requirements, and appeal pathway for finasteride (1 mg and 5 mg) for hair loss and BPH.
A state-by-state guide to Medicaid coverage of finasteride for male pattern hair loss and BPH, including prior authorization criteria, step therapy requirements, appeal strategies, and cash-pay alternatives.
Find out whether TRICARE covers finasteride for hair loss or BPH, what prior authorization looks like, which formulary tier it sits on, and how to appeal a denial step by step.
A guide to UnitedHealthcare finasteride coverage, formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
Finasteride is not FDA-approved for adolescents aged 12, 17. This guide covers off-label dosing considerations, pubertal safety concerns, mental health monitoring, and evidence-based alternatives for early-onset androgenetic alopecia.
Complete finasteride dosing guide for adults aged 30 to 49, covering 1 mg for hair loss and 5 mg for BPH, with trial data, safety monitoring, and clinical considerations.
A clinician-level review of finasteride's interactions with autoimmune conditions, including immune-mediated hair loss, post-finasteride syndrome debate, and prescribing considerations for patients with lupus, psoriasis, or other autoimmune diagnoses.
Does finasteride affect appetite or food cravings? A deep dive into the neurosteroid mechanisms, clinical trial data, and patient-reported outcomes linking finasteride to appetite changes.
A detailed clinical review of how finasteride affects bone mineral density, fracture risk, and skeletal health in men using the drug for AGA or BPH, with primary-literature citations and practical prescribing guidance.
A deep dive into finasteride's long-term cardiovascular effects, covering atherosclerosis, lipid shifts, blood pressure, sexual side effects, and what PCPT, PLESS, and newer cohort data say about heart risk.
A clinician-level review of finasteride's effects on cognition, neurosteroid pathways, post-finasteride syndrome, and what current evidence says about memory, brain fog, and mood.
A comparison of compounded finasteride versus branded Propecia and Proscar, covering bioequivalence, cost, safety, regulatory status, and clinical trial evidence.
How does finasteride cost compare to dutasteride, minoxidil, and other hair-loss and BPH treatments? A breakdown of mechanism, pricing, efficacy, and when to switch.
Evidence-based finasteride dosing for adults ages 50 to 64, covering AGA (1 mg) and BPH (5 mg) indications, polypharmacy interactions, cardiovascular considerations, and monitoring protocols.
A guide to finasteride dosing for men aged 18, 29, covering 1 mg AGA and 5 mg BPH protocols, fertility considerations, sexual side-effect data, and monitoring recommendations.
Evidence-based guide to finasteride use in patients with liver disease, including pharmacokinetic considerations, dose adjustments, and monitoring recommendations for prescribers.
Finasteride requires no dose adjustment in renal impairment. This MD-reviewed guide covers the pharmacokinetic data, hepatic metabolism, and clinical considerations for prescribing finasteride to patients with kidney disease.
A physician-level GRADE analysis of finasteride for androgenetic alopecia and BPH, covering RCT data, effect sizes, certainty ratings, and prescribing guidance.
Finasteride evolution traces 25+ years from oral 1mg to new topical and nanoparticle formulas cutting systemic absorption up to 95% while maintaining DHT reduction.
Finasteride can be taken with or without food. Compare supplement evidence, biotin lab interference, and claims not established in finasteride studies.
Evidence-based guide to finasteride dosing in adults 65 and older, covering BPH and hair loss indications, renal considerations, drug interactions, and deprescribing.
Evidence-based monitoring guide for finasteride use in adults 65 and older, covering PSA adjustments, renal function, sexual side effects, falls risk, and deprescribing timelines.
A guide to how finasteride changes hair density, skin oiliness, and scalp health. Includes real trial data, doses, timelines, and safety context.
Finasteride's terminal half-life is 5 to 6 hours in men 18-60 (8+ hours over 70), but its effect on DHT lasts much longer due to irreversible enzyme binding.
A detailed timeline of finasteride's discovery, FDA approvals, mechanism of action, and clinical development from Merck's 5-alpha reductase research through modern generic availability.
Evidence-based guide to finasteride use in transplant recipients, people living with HIV, patients with liver disease, and other special populations. Covers drug interactions, dose adjustments, and monitoring.
A clinical deep-dive into how finasteride affects liver enzymes, hepatotoxicity risk, and what monitoring is needed for men using 1 mg or 5 mg daily.
A clinician-level review of how finasteride is made, which manufacturers supply it, what caused past shortages, and what patients and prescribers should know about supply risks today.
A physician-level explanation of how finasteride inhibits 5-alpha reductase type II, reduces scalp DHT, and reverses miniaturization in androgenetic alopecia and BPH.
An evidence-based look at finasteride's effects on mood, depression, anxiety, and post-finasteride syndrome, with primary-literature citations and clinical guidance.
A clinician-level review of how finasteride is absorbed, metabolized, and excreted, plus an evidence-based look at its effects on energy expenditure, thermogenesis, and body composition.
A deep dive into finasteride microdosing for androgenetic alopecia, covering dose-response pharmacology, DHT suppression at sub-milligram doses, side-effect considerations, and what a clinician conversation about off-label dosing should cover.
Missed a finasteride dose? Don't double up. Take it the same day if you remember; if your next dose is close, skip it and resume your regular schedule.
A clinical guide to monitoring finasteride in adults aged 30 to 49, covering baseline labs, PSA adjustments, hormonal panels, sexual function screening, and follow-up schedules for both AGA and BPH indications.
A clinical guide to monitoring finasteride in adults aged 50 to 64, covering PSA correction, baseline labs, sexual side-effect tracking, polypharmacy review, and evidence-based timelines.
A complete clinical reference for monitoring finasteride use in adolescents aged 12 to 17, covering growth, hormonal, psychiatric, and sexual health parameters with evidence-based thresholds and timelines.
Evidence-based finasteride monitoring schedule covering baseline labs, PSA adjustments, liver function, hormones, and follow-up exams for men on 1 mg or 5 mg finasteride.
A clinical deep-dive into how finasteride affects muscle mass, strength, and recovery, and the specific strategies men on finasteride can use to protect their gains, prepared by the HealthRX.com Editorial Team.
A guide to finasteride's off-label applications beyond BPH and male pattern hair loss, with trial data and evidence grading for each use.
A guide to finasteride overdose, accidental excess dosing, mechanism of action, and 5-alpha reductase inhibition, with FDA-cited evidence and toxicology data.
A comprehensive guide to finasteride's mechanism of action, patent expiration, generic availability, and clinical evidence for AGA and BPH.
Finasteride has no FDA-approved pediatric dosing for children under 12. Learn why this 5-alpha reductase inhibitor is contraindicated in prepubertal patients, what the evidence says, and when rare exceptions may apply.
Evidence-based guide to monitoring finasteride use in pediatric patients under 12, including lab schedules, growth tracking, hormonal surveillance, and safety protocols for off-label prescribing.
A comprehensive clinical review of finasteride safety in children under 12, covering FDA labeling, hormonal risks, contraindications, and the rare pediatric conditions where off-label use has been studied.
How SRD5A1/SRD5A2 polymorphisms, CYP3A4 variants, and androgen-receptor genetics shape finasteride response, adverse-effect risk, and dosing decisions, with PubMed-cited evidence.
A complete clinical guide to the finasteride pre-surgery hold window: when to stop, why it matters for bleeding risk and hormone labs, and how to restart safely after your procedure.
Finasteride family planning: distinguish maternal use, tablet contact, semen exposure, fertility studies, breastfeeding and medication-pause decisions.
A clinician-grade review of finasteride real-world evidence from patient registries, electronic health record studies, and post-marketing surveillance for hair loss and BPH.
A guide to what happens when you stop finasteride, including hair loss rebound timelines, hormonal changes, post-finasteride syndrome, and how to minimize shedding after discontinuation.
A clinician-grade overview of finasteride's regulatory approvals across the US, EU, Canada, and UK, including approved indications, dose forms, generic availability, and post-market safety actions.
A comprehensive analysis of finasteride's effects on kidney function, including BPH-related obstructive nephropathy, direct renal toxicity data, and clinical guidance for patients with CKD.
A clinical review of finasteride safety data for men aged 30 to 49, covering sexual side effects, mental health signals, post-finasteride syndrome, liver and cardiovascular markers, and monitoring protocols.
A guide to finasteride safety in adults aged 50, 64, covering cardiovascular risk, drug interactions, sexual side effects, prostate cancer screening, and dosing for AGA and BPH.
A clinical review of finasteride safety data, off-label use considerations, growth and hormonal risks, and monitoring requirements for adolescents ages 12 to 17 with male-pattern hair loss.
Evidence-based review of finasteride safety in geriatric patients (65+), covering sexual side effects, PSA masking, cognitive concerns, falls risk, polypharmacy, and when to consider stopping.
Finasteride at ages 18-29: compare actual sexual-effect, mood and fertility studies, distinguish 1 mg from 5 mg evidence, and assess topical alternatives.
Finasteride side effects: trials showed sexual problems in 3.8% of users vs 2.1% on placebo. FDA labels now add warnings for depression and suicidality.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.